Security
Innate Pharma, Marseille Shares Nom Cat -A- (France) · IPHYF
IPHYFOTCCommon stockCurrentCIK 1598599Updated Oct 1, 2026
Name history
Innate Pharma, SA · through Jan 31, 2014
IPHYF price & chart
Loading TradingView…
OTC:IPHYF on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | -49,177,000Source | -49,471,000Source | -7,570,000Source | -58,103,000Source |
| Additional Financial Items | ||||
| AdjustmentsForFinanceCostsEUR | — | — | 0Source | 0Source |
| AdjustmentsForFinanceIncomeEUR | 0Source | 0Source | 991,000Source | 0Source |
| AdjustmentsForSharebasedPaymentsEUR | 2,567,000Source | 3,944,000Source | 4,256,000Source | 4,249,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsEUR | 1,362,000Source | -885,000Source | 544,000Source | -912,000Source |
| GeneralAndAdministrativeExpenseEUR | 19,394,000Source | — | — | — |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | -6,500,000Source | -8,600,000Source | — | — |
| IncreaseDecreaseInWorkingCapitalEUR | 10,632,000Source | -39,162,000Source | 32,091,000Source | 12,502,000Source |
| InterestPaidClassifiedAsFinancingActivitiesEUR | — | — | 0Source | 0Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | 400,000Source | 1,300,000Source | — | — |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | 1,800,000Source | 1,900,000Source | — | — |
| OtherAdjustmentsToReconcileProfitLossEUR | -2,000Source | 24,000Source | 6,000Source | 15,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | 0Source | 0Source | 0Source | 0Source |
| ProceedsFromIssuingSharesEUR | 14,981,000Source | 2,928,000Source | 395,000Source | 198,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | 0Source | 0Source | 150,000Source | 0Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 0Source | 0Source | 2,000,000Source | 587,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | 8,911,000Source | 8,936,000Source | 2,361,000Source | 2,026,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseEUR | — | 19,716,000Source | 18,288,000Source | 22,436,000Source |
| Total RevenueEUR | 9,005,000Source | 20,121,000Source | 61,641,000Source | 57,674,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source | 0.25Source |
| AverageEffectiveTaxRatenumber | — | 0Source | 0Source | 0Source |
| BasicEarningsLossPerShareEUR/shares | -0.55Source | -0.61Source | -0.09Source | -0.73Source |
| DeferredTaxExpenseIncomeEUR | 0Source | 0Source | 0Source | 0Source |
| DepreciationAndAmortisationExpenseEUR | 1,384,000Source | 1,988,000Source | 5,093,000Source | 4,424,000Source |
| DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssetsEUR | 1,384,000Source | 1,576,000Source | — | — |
| DilutedEarningsLossPerShareEUR/shares | -0.55Source | -0.61Source | -0.09Source | -0.73Source |
| EmployeeBenefitsExpenseEUR | 27,363,000Source | 26,092,000Source | 25,964,000Source | 26,603,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | 2,567,000Source | 3,944,000Source | 4,256,000Source | 4,249,000Source |
| FinanceCostsEUR | 3,120,000Source | 3,975,000Source | 1,835,000Source | 5,321,000Source |
| FinanceIncomeEUR | 7,951,000Source | 6,079,000Source | 6,934,000Source | 4,775,000Source |
| GeneralAndAdministrativeExpenseEUR | 19,394,000Source | — | — | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillEUR | 0Source | 0Source | 0Source | 41,000,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseEUR | 440,000Source | 566,000Source | 640,000Source | 288,000Source |
| NetForeignExchangeLossEUR | 2,680,000Source | 3,409,000Source | 1,195,000Source | 2,983,000Source |
| OtherIncomeEUR | 13,000Source | 11,000Source | 11,000Source | 59,000Source |
| OtherOperatingIncomeExpenseEUR | -1,978,000Source | -1,927,000Source | -872,000Source | -795,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansEUR | 1,286,000Source | 1,251,000Source | 1,283,000Source | 1,432,000Source |
| ProfitLossBeforeTaxEUR | -49,177,000Source | -49,471,000Source | -7,570,000Source | -57,972,000Source |
| ProfitLossFromOperatingActivitiesEUR | -54,008,000Source | -51,575,000Source | -12,669,000Source | -57,425,000Source |
| ResearchAndDevelopmentExpenseEUR | 43,620,000Source | 51,980,000Source | 56,022,000Source | 51,663,000Source |